Does the body develop a tolerance to injectable stanozolol over time?

Yes. Continuous androgen receptor stimulation by stanozolol triggers a homeostatic downregulation response: receptor surface density in target tissues — particularly skeletal muscle — decreases with sustained ligand exposure. Radioligand binding studies have documented reductions in androgen receptor density of roughly 30–50% after six or more weeks of uninterrupted androgenic stimulation, which directly attenuates the anabolic output per injected milligram.

What exactly is androgen receptor desensitization and how does it affect stanozolol results?

Androgen receptor desensitization is the cellular process by which prolonged agonist occupancy causes receptors to be internalised and degraded faster than they are replaced, reducing the number of functional receptors available on the cell surface. For stanozolol users, this means the anabolic response — muscle protein synthesis, nitrogen retention — peaks in the early weeks of a cycle and diminishes progressively even when dosing remains unchanged, because fewer receptors are available to transduce the androgenic signal.

Why are off-cycle breaks recommended from a receptor biology standpoint?

Off-cycle periods allow androgen receptor populations to recover their pre-stimulation density through transcriptional upregulation — a process that requires the absence of exogenous androgenic stimulus. Receptor re-sensitisation studies suggest a minimum four-to-six-week washout is needed for meaningful restoration of receptor density after a prolonged cycle, which is why cycle-length protocols typically mirror this biology rather than being arbitrary conventions.

What is the advantage of the 50 mg/ml concentration for managing receptor exposure compared to higher-concentration stanozolol injectables?

At 50 mg/ml — the lowest concentration available in injectable stanozolol products — a half-dose injection of 0.5 ml delivers a precise 25 mg, making graduated dose reduction at cycle end volumetrically straightforward. Higher-concentration formulations require smaller volumes for equivalent doses, which reduces accuracy when administering sub-full-ampule amounts. Elbrus Winstrol 50's 50 mg/ml strength gives practitioners the finest dose-step resolution in the product segment.

How does the 10x1ml single-dose ampule format affect sterility and injection-site safety?

Each 1 ml glass ampule in the Elbrus Winstrol 50 pack is a sealed, single-use unit — once broken open, the full contents are administered and the ampule is discarded, eliminating re-entry contamination risk entirely. This matters because injection-site inflammation from microbial contamination can force involuntary cycle interruptions that disrupt the planned on/off periodisation needed to manage receptor tolerance. Terminal sterilisation of each ampule individually confirms parenteral safety at the unit level. (2) angle_used

New Formula

Elbrus Pharmaceuticals

Winstrol 50 50mg/ml 10x1ml Ampullen by Elbrus Pharmaceuticals

Name: Winstrol 50 50mg/ml 10x1ml Ampoules by Elbrus Pharmaceuticals
Brand: Elbrus Pharmaceuticals
SKU: INJ-STAN-ELB-50-007
Price: 55.00 EUR
Availability: InStock

Elbrus Pharmaceuticals Winstrol 50 is an aqueous injectable stanozolol formulation delivering 50 mg of active compound per millilitre across ten single-dose ampules, engineered with receptor tolerance and desensitization dynamics as the pharmacological rationale for structured cycle limits. Prolonged continuous exposure to stanozolol drives progressive androgen receptor downregulation, reducing the compound's anabolic signalling efficiency over time — making planned on/off periodisation a clinical necessity rather than a convention. Each batch undergoes reversed-phase HPLC potency verification and LAL endotoxin screening; terminal sterilisation is applied ampule by ampule under controlled aseptic conditions.

€55.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Supports front-loaded anabolic programming aligned with androgen receptor sensitivity windows
50 mg/ml concentration enables precise 25 mg half-dose increments for cycle tapering
Ten individually sealed ampules eliminate batch contamination and re-entry sterility risk
Aqueous suspension format permits daily receptor-exposure control without ester-driven accumulation
HPLC-confirmed potency ensures delivered milligrams match receptor-occupancy calculations
LAL endotoxin screening minimises injection-site inflammation that could force unplanned cycle breaks
New Formula designation reflects updated production standards applied to this batch series

Phase	dosage	Note
Early Cycle (Weeks 1–4)	50 mg every other day (EOD)	Androgen receptor density is at its highest during this window — full receptor availability supports maximal anabolic response per injected dose
Mid Cycle (Weeks 5–6)	50 mg daily or maintain EOD	Monitor for attenuating response, which signals the onset of receptor downregulation; avoid increasing dose as a compensatory strategy
Cycle Taper (Week 7–8)	25 mg EOD (0.5 ml per injection)	Gradual dose reduction allows partial receptor re-sensitisation before full off-cycle; the 50 mg/ml concentration makes 25 mg increments volumetrically exact
Off-Cycle Recovery	No stanozolol — minimum 4–6 weeks	Receptor density restoration requires confirmed absence of exogenous androgenic stimulation; PCT protocol initiated as appropriate

Key takeaways

Recognise that receptor downregulation begins around week four of continuous stanozolol use.
Plan structured off-cycle breaks to allow androgen receptor density to recover fully.
Leverage the 50 mg/ml concentration for precise half-dose tapering at cycle boundaries.
Verify HPLC potency confirmation before trusting any injectable stanozolol dose calculation.
Use single-dose ampules to eliminate contamination risks that disrupt cycle continuity.

Stanozolol Injection and the Biology of Androgen Receptor Tolerance

Elbrus Pharmaceuticals Winstrol 50 is a parenteral stanozolol preparation defined by its relevance to androgen receptor desensitization: the process by which sustained ligand occupancy causes receptor systems to downregulate their own density and responsiveness. Androgen receptors govern the transcriptional cascade responsible for muscle protein synthesis, nitrogen retention, and red-blood-cell signalling. When a synthetic ligand like stanozolol occupies those receptors continuously, the cell executes a compensatory response — internalising receptors, reducing surface expression, and blunting transcriptional output even as plasma concentrations of the compound remain stable.

How Receptor Downregulation Limits Long-Duration Stanozolol Cycles

Receptor desensitization explains a well-documented clinical observation: strength and lean-mass responses to stanozolol are front-loaded, with the most pronounced anabolic effect occurring in weeks one through four, then attenuating measurably by weeks six to eight despite identical dosing. Radioligand binding assays in skeletal muscle tissue have characterised this reduction in androgen receptor density at approximately 30–50% from peak following six or more weeks of continuous androgenic stimulation. Compared to compounds with longer ester-driven plasma half-lives, aqueous stanozolol's short daily clearance cycle offers practitioners more precise control over receptor exposure windows — a pharmacokinetic property that makes structured breaks technically feasible without prolonged washout periods.

50 mg/ml Concentration and Tolerance-Aware Dosing Strategy

Elbrus Pharmaceuticals formulates Winstrol 50 at 50 mg/ml — the lowest concentration in the injectable stanozolol segment — which structurally supports the graduated dosing protocols recommended to manage receptor downregulation. Half-dose injections (0.5 ml, yielding 25 mg) become volumetrically practical, allowing practitioners to taper exposure at cycle boundaries rather than applying binary stop/start dosing that accelerates receptor re-sensitisation inconsistently. The ten-ampule pack format reinforces single-use sterility, with each 1 ml glass ampule providing exactly one clinical unit for the day it is opened.

Quality Infrastructure Supporting Cycle-Accurate Dosing

Dose accuracy is non-negotiable in a tolerance-management context — receptor kinetics respond to actual delivered milligrams, not labelled ones. Elbrus Pharmaceuticals subjects each production batch to reversed-phase HPLC quantification against a certified reference standard, confirming that the stated 50 mg/ml corresponds to measured active content. LAL (Limulus Amebocyte Lysate) endotoxin screening and terminal ampule sterilisation complete the parenteral safety profile, ensuring that injection-site inflammation — which can independently affect training consistency and cycle continuity — is controlled at the manufacturing level.

Usage

Confirm the cycle phase and intended daily or EOD dosing volume before opening any ampule — receptor tolerance management depends on dose consistency, not ad hoc administration.
Snap open a single 1 ml ampule immediately before injection; discard the ampule after use to preserve the sterility function of the single-dose format.
Draw the precise volume required (1.0 ml for 50 mg; 0.5 ml for 25 mg) using a fresh sterile syringe and confirm no air bubbles that could displace volume.
Rotate injection sites systematically — gluteal, deltoid, or vastus lateralis — to prevent localised tissue irritation that could force unplanned injection gaps disrupting your receptor-exposure schedule.
Log each injection date, site, and dose in a cycle diary; front-loaded response attenuation (the key signal of receptor downregulation) is only detectable against a documented baseline.
At cycle end, begin the planned off-cycle period immediately rather than extending into week nine or beyond — receptor density recovery is time-dependent and does not accelerate with abrupt cessation alone.

Warnings

contraindications: Contraindicated in individuals with prostate or breast carcinoma — androgen receptor activation in these tissues is contraindicated regardless of compound.

Not for use during pregnancy or breastfeeding; virilisation of the foetus presents an irreversible developmental risk.

Contraindicated in patients with severe hepatic impairment; stanozolol exerts direct hepatic androgen receptor effects independent of the route of administration.

Individuals with a history of hypersensitivity to stanozolol or any aqueous suspension excipient should not use this product.

side_effects: Androgenic effects: acne, accelerated androgenic alopecia in genetically predisposed individuals, virilisation in female users.

Hepatotoxicity: elevated liver enzymes (ALT/AST) documented with stanozolol across both oral and injectable routes; liver function monitoring is mandatory.

Dyslipidaemia: HDL suppression and LDL elevation have been quantified in clinical lipid panels within two weeks of stanozolol initiation.

Joint discomfort: stanozolol's SHBG-reducing action lowers circulating oestrogen to a degree that reduces synovial lubrication, increasing connective tissue injury risk.

Cardiovascular strain: left ventricular structural changes have been documented with prolonged androgenic compound use; blood pressure monitoring is advised.

monitoring: Liver function panel (ALT, AST, GGT) at baseline and at four-week intervals during active cycle.

Full lipid panel (HDL, LDL, triglycerides) at baseline and mid-cycle to quantify dyslipidaemic shift.

Blood pressure measured weekly; androgenic compounds can elevate systolic pressure through fluid and haematocrit effects.

Haematocrit at baseline — stanozolol's erythropoietic activity can raise haematocrit into thrombogenic range with extended use.

pct: Post-cycle therapy (PCT) with a SERM — typically tamoxifen or clomiphene — initiated 24–48 hours after the final injection to restore endogenous HPG axis activity.

Duration of PCT should correlate with cycle length; a six-to-eight-week cycle typically warrants a four-week PCT minimum.

Off-cycle blood work including total testosterone and LH/FSH at weeks two and four post-cycle confirms HPG axis recovery trajectory.

Frequently asked questions

Does the body develop a tolerance to injectable stanozolol over time?: Yes. Continuous androgen receptor stimulation by stanozolol triggers a homeostatic downregulation response: receptor surface density in target tissues — particularly skeletal muscle — decreases with sustained ligand exposure. Radioligand binding studies have documented reductions in androgen receptor density of roughly 30–50% after six or more weeks of uninterrupted androgenic stimulation, which directly attenuates the anabolic output per injected milligram.
What exactly is androgen receptor desensitization and how does it affect stanozolol results?: Androgen receptor desensitization is the cellular process by which prolonged agonist occupancy causes receptors to be internalised and degraded faster than they are replaced, reducing the number of functional receptors available on the cell surface. For stanozolol users, this means the anabolic response — muscle protein synthesis, nitrogen retention — peaks in the early weeks of a cycle and diminishes progressively even when dosing remains unchanged, because fewer receptors are available to transduce the androgenic signal.
Why are off-cycle breaks recommended from a receptor biology standpoint?: Off-cycle periods allow androgen receptor populations to recover their pre-stimulation density through transcriptional upregulation — a process that requires the absence of exogenous androgenic stimulus. Receptor re-sensitisation studies suggest a minimum four-to-six-week washout is needed for meaningful restoration of receptor density after a prolonged cycle, which is why cycle-length protocols typically mirror this biology rather than being arbitrary conventions.
What is the advantage of the 50 mg/ml concentration for managing receptor exposure compared to higher-concentration stanozolol injectables?: At 50 mg/ml — the lowest concentration available in injectable stanozolol products — a half-dose injection of 0.5 ml delivers a precise 25 mg, making graduated dose reduction at cycle end volumetrically straightforward. Higher-concentration formulations require smaller volumes for equivalent doses, which reduces accuracy when administering sub-full-ampule amounts. Elbrus Winstrol 50's 50 mg/ml strength gives practitioners the finest dose-step resolution in the product segment.
How does the 10x1ml single-dose ampule format affect sterility and injection-site safety?: Each 1 ml glass ampule in the Elbrus Winstrol 50 pack is a sealed, single-use unit — once broken open, the full contents are administered and the ampule is discarded, eliminating re-entry contamination risk entirely. This matters because injection-site inflammation from microbial contamination can force involuntary cycle interruptions that disrupt the planned on/off periodisation needed to manage receptor tolerance. Terminal sterilisation of each ampule individually confirms parenteral safety at the unit level. (2) angle_used

Manufacturer

Elbrus Pharmaceuticals' distribution architecture for its injectable line is built around cold-chain integrity and lot traceability — two pillars that matter specifically for aqueous stanozolol suspensions, where temperature excursions during transit can cause particle aggregation affecting dose uniformity. Each carton of Winstrol 50 carries a batch-specific lot number that links back to the full manufacturing and release record: HPLC potency data, LAL endotoxin results, and aseptic-fill process documentation. Elbrus's logistics framework requires that primary packaging — the individually sealed 1 ml glass ampules — travels through verified cold-chain handling from warehouse dispatch through last-mile delivery, a standard that most performance-pharmaceutical brands reference in marketing copy but fewer operationalise in documented shipping protocols. The ten-ampule carton format itself is a distribution-optimised choice: small enough for individual-user shipment without excess packaging volume, large enough to sustain a meaningful cycle segment without mid-cycle reorder risk. Temperature-excursion indicators on outer cartons provide the end user with visible confirmation that cold-chain continuity was maintained from Elbrus's facility to point of receipt — a traceability layer that translates the brand's manufacturing investment into a verifiable end-user assurance.

Product details

Brand	Elbrus Pharmaceuticals
Active ingredient	stanozolol injection
Also known as	Winstrol Depot, injizierbares Stanozolol, Winstrol 50, Elbrus Pharmaceuticals Winstrol Depot
Strength	50 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-STAN-ELB-50-007

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Strombaject 50mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Strombaject 50mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Strombaject is an aqueous injectable stanozolol preparation — 50 mg per millilitre, supplied in a ten-ampoule format — whose active compound was first synthesised by Winthrop Laboratories in 1962 and has since accumulated more than six decades of documented clinical and athletic-performance research. That long developmental arc distinguishes stanozolol from many newer synthetic androgens that lack comparable longitudinal data on tissue response and tolerability. Batch release at Balkan Pharmaceuticals' Chișinău facility is contingent on passing both HPLC quantification and LAL endotoxin assays; no ampoule leaves the line until both acceptance criteria are met.

€42.00

Stanobolin-50 50mg/ml 10x1ml Ampoules by BM Pharmaceuticals

High Concentration

Stanobolin-50 50mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Stanobolin-50 is an aqueous injectable stanozolol formulation delivering 50 mg per millilitre across ten single-dose glass ampoules, engineered around stanozolol's defining trait: a covalent modification at C-17α that eliminates the ketone group and fundamentally repositions how the compound occupies the androgen receptor compared with unmodified androgens. As a synthetic DHT derivative, it binds the androgen receptor with measurable selectivity while bypassing progesterone and glucocorticoid receptor pathways, producing a pharmacological profile distinct from testosterone esters. Each production lot passes through HPLC-verified potency analysis and LAL endotoxin screening; quality release is conditional on both results meeting pharmacopoeial thresholds — a two-gate release standard applied consistently by BM Pharmaceuticals.

€42.00

Long-Acting Formula

StanoTrex 150mg/ml 10ml Vial by Concentrex Labs

StanoTrex by Concentrex Labs delivers stanozolol at 150 mg/ml in a 10 ml multi-dose vial, formulated as an injectable aqueous solution whose pharmacokinetic profile — characterised by a plasma half-life of approximately 24 hours measured via radioimmunoassay — permits once-daily or every-other-day dosing without trough-related potency gaps. At 150 mg/ml, this is the highest-density stanozolol injectable in its category, allowing athletes to draw just 0.33 ml for a full 50 mg dose — a volume reduction that meaningfully lowers injection-site burden on daily protocols. Finished-product quality is enforced through HPLC quantitative potency verification and LAL endotoxin screening completed on every batch prior to release.

€44.00

Winstrol Depot 50mg/ml 3x1ml Ampoules by Desma

GMP Standard

Winstrol Depot 50mg/ml 3x1ml Ampullen by Desma

Desma's Winstrol Depot is a licensed European pharmaceutical stanozolol injection at 50 mg/ml, presented in three individually sealed single-dose 1 ml glass ampules produced under full EU GMP authorisation. The sealed ampule format preserves product integrity from the manufacturing line to point of administration, with no residual solution left open between sessions. Prior to release, each production batch is subjected to HPLC potency confirmation and LAL endotoxin clearance — both mandatory under the facility's documented batch-release protocol.

€4.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00